As an executive in the biotechnology industry, Dr. Clay Siegall has years of experience developing targeted drug therapies to treat cancer. He says that cancer is a disease many people fear developing and millions die from it each year. The most common forms of cancer are prostate cancer for men and breast cancer for women. In recent years there has also been an uptick in people being diagnosed with skin cancer, colon cancer, and other forms of this disease. There are many companies in the industry developing new ways to both quickly diagnose cancer as well as treat it. As Dr. Clay Siegall points out, the sooner cancer is caught the better it can be successfully treated.
Genetic sequencing is a technology that Dr. Clay Siegall is very interested. He says that genetic testing today is both quicker than it used to be and less expensive. In regards to cancer research specifically he says that it could lead to new ways to diagnose and treat cancer in ways that are much more effective than the conventional approach to cancer care, without all of the terrible side effects like nausea, pain, and losing hair. Each person has around 20,000 genes and they connect in a way that creates a unique DNA code for each person. By being able to evaluate this for each person their care can be more individualized.
Clay Siegall is a biotechnology industry leader. He heads Seattle Genetics, a company he founded in 1998. His company creates targeted drug therapies using antibody drug conjugates. This approach results in the drugs his company creates only killing cancer cells. This is much better than conventional cancer drugs which pretty much indiscriminately kill cells. His approach is safer, more effective, and has far fewer side effects for the patient.
After earning his Ph.D. in genetics Dr. Clay Siegall spent 23 years working in biotechnology before founding Seattle Genetics. He worked for the National Institute of Health as a researcher for 17 years. He then moved to the Seattle, WA area in order to work as a researcher for Bristol-Meyer Squibb.